Hoomer, he saying you will get the results as he t
Post# of 36566
(Total Views: 246)
Posted On: 02/21/2021 2:38:54 PM
Hoomer, he saying you will get the results as he told us on the CC. Certification is just common knowledge. He’s typing fast and said that part because it’s as common as needing a period on the end of a sentence or something similar.
New investors don’t be confused by all of these posts. Generex and their subsidiary NuGenerex Immuno Oncology, were requested by the FDA to conduct an immunogenicity study on their Ii-key SARS Covid-19 peptide vaccine. These results are pending for any day now. Generex gave guidance of being 7–10 days away during a CC that was 9 business days ago. Generex communicates often with their shareholders, it obviously don’t control which exact day results are certified and ready to be worded in a press release. It’s an exciting prospect to have these types of results because they may indicate or prove that the NuGenerex peptide vaccine has superior qualities to any currently approved for emergency usage by the FDA. These results will lead to a FDA IND and Phase 1-3 studies funded by Generex’s partners. They also will be more fully revealed to the scientific and biotech/pharmaceutical community in a peee reviewed publication.
And during these exciting events a bigger one will occur. NuGenerex has been spun out of Generex to be their own public company. Generex is helping to list NuGenerex (ticker to be NGIO) onto Nasdaq.
Everything else is parsing over words.
New investors don’t be confused by all of these posts. Generex and their subsidiary NuGenerex Immuno Oncology, were requested by the FDA to conduct an immunogenicity study on their Ii-key SARS Covid-19 peptide vaccine. These results are pending for any day now. Generex gave guidance of being 7–10 days away during a CC that was 9 business days ago. Generex communicates often with their shareholders, it obviously don’t control which exact day results are certified and ready to be worded in a press release. It’s an exciting prospect to have these types of results because they may indicate or prove that the NuGenerex peptide vaccine has superior qualities to any currently approved for emergency usage by the FDA. These results will lead to a FDA IND and Phase 1-3 studies funded by Generex’s partners. They also will be more fully revealed to the scientific and biotech/pharmaceutical community in a peee reviewed publication.
And during these exciting events a bigger one will occur. NuGenerex has been spun out of Generex to be their own public company. Generex is helping to list NuGenerex (ticker to be NGIO) onto Nasdaq.
Everything else is parsing over words.
(5)
(0)